Home › Funds › Affinity Asset Advisors, LLC › MDGL

Affinity Asset Advisors, LLC position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

Affinity Asset Advisors, LLC reported holding 30,000 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$15.1M, representing 0.70% of its reported portfolio and ranking #38 among its reported holdings. Affinity Asset Advisors, LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)30.00K sh
Reported value held$15.12M
Portfolio Weight0.70%
First reportedQ3 2023
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's MDGL position evolved

Affinity Asset Advisors, LLC first disclosed a stake in MDGL in Q3 2023 at 85,000 shares (US$12.4M). The position peaked in Q3 2025 at 115,000 shares, worth US$52.7M. Across 13 filings, Affinity Asset Advisors, LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 30,000 shares valued at US$15.1M — a reduction of -10,000 shares quarter over quarter.. Notable position changes include a 44% increase in Q3 2025 (shares rose 27% over the following quarter), a 73% trim in Q4 2025 (shares fell 10% over the following quarter), a 77% increase in Q1 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 85.00K $12.41M New
Q4 2023 100.00K $23.14M Add
Q1 2024 115.00K $30.71M Add
Q2 2024 110.00K $30.82M Reduce
Q3 2024 100.00K $21.22M Reduce
Q4 2024 82.50K $25.46M Reduce
Q1 2025 80.00K $26.50M Reduce
Q2 2025 80.00K $24.21M Hold
Q3 2025 115.00K $52.75M Add
Q4 2025 31.13K $18.13M Reduce
Q1 2026 55.00K $28.79M Add
Q2 2026 40.00K $21.48M Reduce
Q3 2026 30.00K $15.12M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held MDGL?

Affinity Asset Advisors, LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Affinity Asset Advisors, LLC's current position in MDGL?

As of Q3 2026, Affinity Asset Advisors, LLC holds 30.00K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $15.12M, representing 0.70% of its reported portfolio and ranking #38.

Has Affinity Asset Advisors, LLC been buying or selling MDGL?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC reduced its position in MDGL. The position peaked in Q3 2025 at 115.00K shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.